Executives
?
Waldman Lawrence
Director
Apyx Medical Corporation
US, Clearwater [HQ]
CIK
1516592
Data Source
We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.
Latest Information
Shares :
13,563
Price per Share :
$1.40
Equivalence :
$18,988.20
Transaction History
-
M13,563 Shares After TransactionValue : $37,840.77$22,320.00Transaction Date : 05/19/22
-
Footnotes
-
-
Footnotes:No footnote found.
-
A48,000 Shares After TransactionValue : $240,960.00$40,160.00Transaction Date : 08/17/22
-
Footnotes
-
-
Footnotes:#1 Common Stock issued pursuant to the Corporations 2016 share incentive plan, vest 4,000 shares on Aug. 17, 2022 and December 31, 2022, provided that such individual is still serving as a Director as of the vesting date.
-
M5,338 Shares After TransactionValue : $15,853.86$15,853.86Transaction Date : 07/12/23
-
Footnotes
-
-
Footnotes:#1 Represents a "net exercise" of outstanding stock options. The Reporting Person received 5,338 shares of common stock on net exercise of an option to purchase 12,000 shares of common stock.#2 The Reporting Person transferred this option to a Spousal Lifetime Access Trust (the "SLAT"). The Reporting Person's spouse and children are trustees of the SLAT.#3 The Reporting Person disclaims beneficial ownership of all securities held by the SLAT, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of the Reporting Person's pecuniary interest therein, if any.
-
M37,563 Shares After TransactionValue : $95,410.02$60,960.00Transaction Date : 07/11/22
-
Footnotes
-
-
Footnotes:No footnote found.
-
A40,000 Shares After TransactionValue : $188,000.00$45,120.00Transaction Date : 01/15/21
-
Footnotes
-
-
Footnotes:#1 Common Stock issued pursuant to the Corporations 2016 share Incentive Plan, vest as to 2,400 shares on each March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021, or as the date of the 2021 annual meeting of shareholders but in no event earlier than November 15, 2021 provided that such individual is still serving as a Director as of the vesting date.